COUNTERPOINT: Routine Use of Autologous Stem Cell Transplantation in Multiple Myeloma
Over the last decade, it has become clear that there are many different subsets of multiple myeloma, all with different biological drivers and a variety of patient-based characteristics that influence therapeutic efficacy.Â
Oncology (Williston Park)
In The News
American Society of Hematology 2016 Annual Meeting
Session 731. Clinical Autologous Transplantation: Results: Clinical Autologous Transplantation in Myeloma I
American Society of Hematology 2016 Annual Meeting
Session 653. Myeloma: Therapy, excluding Transplantation: IMiD/Proteasome Inhibitor Combinations and Maintenance Therapy
American Society of Hematology 2016 Annual Meeting
Abstract 1143: Lenalidomide Is a Highly Effective Maintenance Therapy in Myeloma Patients of All Ages; Results of the Phase III Myeloma XI Study
American Society of Hematology 2016 Annual Meeting
Abstract 673: Intensification Therapy with Bortezomib-Melphalan-Prednisone Versus Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma: An Intergroup, Multicenter, Phase III Study of the European Myeloma Network (EMN02/HO95 MM Trial)
In The Literature
Bone Marrow Transplant